BioSpace News Archive

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, MTX and HCQ) will be a contracted covered service with TRICARE East managed care support contractor Humana Military to optimize the care of these patients.

Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced 48-week, open-label efficacy and safety data from the Phase 3 CHIASMA OPTIMAL

Surgalign Holdings, Inc. (Nasdaq: SRGA), a leading global pure-play spine company focused on advancing spine surgery and improving patient outcomes, today announced it plans to release financial results from the second quarter 2020 on Tuesday, August 4, 2020, prior to the market open.

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that it has entered into a definitive agreement to sell its Priority Review Voucher (PRV) to Merck, known as MSD outside the United States and Canada.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS™) technology, announced today it will report financial results for the second quarter 2020 after market close on Monday, August 10, 2020.

Oncologie, Inc., a precision medicine company using an innovative RNA-based biomarker platform to develop novel, targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of Oncologie, will be presenting a corporate overview at the following investor conferences in August:

The Board of Directors of BD has declared a quarterly dividend of $0.79 per common share, payable on September 30, 2020 to holders of record on September 9, 2020.

FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announced today that its College Station, Texas, site will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed,

Big Effect Trial (BET) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) to advance high priority therapeutic candidates for COVID-19

Tilray Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a global pioneer in cannabis production, research, cultivation and distribution, announced today it will report results for the second quarter ended June 30, 2020 on Monday, August 10, 2020 after market close.